BTIG Reiterates Buy on Solventum, Maintains $95 Price Target
BTIG analyst Ryan Zimmerman reiterates Solventum (NYSE:SOLV) with a Buy and maintains $95 price target.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga